Alkermes' Acquisition Proves To Be Game-Changer
Drugmaker Alkermes' (ALKS) acquisition last year of Elan Drug Technologies was a masterstroke for the company, and institutions are reacting the way you'd expect -- they're buying. As soon as the ink dried on the billion-dollar buy, Alkermes cut its tax liabilities. How? By moving its base from Waltham, Mass. (which is still home to its R&D center) to Dublin, Ireland. You may not think of Western Europe as a low-tax alternative, but Ireland makes
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here